Ciocirlan M, Lapalus M G, Hervieu V, Souquet J C, Napoléon B, Scoazec J Y, Lefort C, Saurin J C, Ponchon T
Gastroenterology and Hepatology Centre, Fundeni Clinical Institute, Bucharest, Romania.
Endoscopy. 2007 Jan;39(1):24-9. doi: 10.1055/s-2006-945182.
BACK AND STUDY AIMS: Endoscopic mucosal resection (EMR) is used to treat premalignant and malignant digestive tract lesions. This report presents the efficacy and safety of EMR for squamous superficial neoplastic esophageal lesions.
A retrospective cohort study presented data from 51 patients with 54 lesions over an 8-year period, between November 1997 and September 2005. Dysplasas or mucosal (m) T1 carcinomas were treated with repeated EMR until there was a complete local remission. Patients with submucosal (sm) T1 carcinomas were treated with repeated EMR until there was a complete local remission. Patients with submucosal (sm) T1 carcinomas or more advanced stage were offered surgery or chemoradiotherapy.
There was no mortality, perforation, or major hemorrhage, and there were three easily dilated stenoses. Of the patients, 16 had lesions graded as T1sm or more advanced and one patient was found to have normal tissue post EMR. Complete local remission was achieved in 31 of the 34 patients with dysplasia or T1 m cancers (91%). There was no distant relapse and there was local disease recurrence in eight of the 31 patients (26%). The 5-year survival rate was 95%.
EMR for squamous superficial neoplastic lesions of the esophagus is safe and provides satisfactory survival results.
背景与研究目的:内镜黏膜切除术(EMR)用于治疗消化道癌前病变和恶性病变。本报告介绍了EMR治疗食管鳞状上皮浅表性肿瘤病变的疗效和安全性。
一项回顾性队列研究呈现了1997年11月至2005年9月8年间51例患者54处病变的数据。异型增生或黏膜(m)T1期癌采用重复EMR治疗,直至局部完全缓解。黏膜下(sm)T1期癌患者采用重复EMR治疗,直至局部完全缓解。黏膜下(sm)T1期癌或更晚期患者接受手术或放化疗。
无死亡、穿孔或大出血发生,有3处狭窄易于扩张。患者中,16例病变分级为T1sm或更晚期,1例患者EMR术后组织正常。34例异型增生或T1 m期癌患者中31例(91%)实现局部完全缓解。无远处复发,31例患者中有8例(26%)出现局部疾病复发。5年生存率为95%。
EMR治疗食管鳞状上皮浅表性肿瘤病变安全,生存结果令人满意。